Compare ROMA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | ZURA |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.0M | 455.4M |
| IPO Year | 2022 | 2021 |
| Metric | ROMA | ZURA |
|---|---|---|
| Price | $8.73 | $5.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 4.6K | ★ 737.0K |
| Earning Date | 12-23-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $1.88 |
| 52 Week High | $11.77 | $7.25 |
| Indicator | ROMA | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 53.49 |
| Support Level | $7.56 | $5.44 |
| Resistance Level | $9.75 | $5.87 |
| Average True Range (ATR) | 0.53 | 0.29 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 15.52 | 45.83 |
Roma Green Finance Ltd is a professional specialist in the provision of environmental, social and governance (ESG), sustainability and climate change related advisory services through its operating subsidiaries in Hong Kong and Singapore. Its services include Sustainability Program Development, ESG Reporting, Corporate Governance and Risk Management, Climate Change Strategies and Solutions, Environmental Audit, ESG Rating Support and Shareholder Communication, and Education and Training. It operates in one reporting business segment in Hong Kong and Singapore, of which the majority of revenue is derived from Hong Kong.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.